Form 8-K - Current report:
SEC Accession No. 0001193125-24-278717
Filing Date
2024-12-13
Accepted
2024-12-13 17:30:31
Documents
21
Period of Report
2024-12-12
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d859956d8k.htm   iXBRL 8-K 36622
2 EX-1.1 d859956dex11.htm EX-1.1 203357
3 EX-4.1 d859956dex41.htm EX-4.1 69057
4 EX-5.1 d859956dex51.htm EX-5.1 9602
5 EX-99.1 d859956dex991.htm EX-99.1 9902
6 EX-99.2 d859956dex992.htm EX-99.2 10168
10 GRAPHIC g859956dsp65.jpg GRAPHIC 7307
11 GRAPHIC g859956dsp67a.jpg GRAPHIC 15080
12 GRAPHIC g859956dsp69.jpg GRAPHIC 9732
  Complete submission text file 0001193125-24-278717.txt   602244

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA cadl-20241212.xsd EX-101.SCH 2854
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE cadl-20241212_lab.xml EX-101.LAB 18738
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE cadl-20241212_pre.xml EX-101.PRE 11710
23 EXTRACTED XBRL INSTANCE DOCUMENT d859956d8k_htm.xml XML 3765
Mailing Address 117 KENDRICK STREET SUITE 450 NEEDHAM MA 02494
Business Address 117 KENDRICK STREET SUITE 450 NEEDHAM MA 02494 617-916-5445
Candel Therapeutics, Inc. (Filer) CIK: 0001841387 (see all company filings)

EIN.: 522214851 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40629 | Film No.: 241549495
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)